Daewoong Pharmaceutical Co., Ltd. South Korea

The ultra-small 1cm² patch, which only needs to be applied once a week, dramatically increases user convenienceDaewoong Therapeutics employs the 'CLOPAM' platform to develop 'advanced formulations,' with plans for commercialization by 2028CEO Seung-Ho Jeon states, "By developing the GLP-1 analogue patch-type formulation, we aim to meet the unmet needs of patients and medical professionals."View original content:https://www.prnewswire.co.uk/news-releases/daewoong-pharmaceutical-to-initiate-clinical-trials-early-next-year-for-innovative-glp-1-obesity-treatment-with-advanced-microneedle-technology-for-sustained-weekly-efficacy-301978673.html